University of Southern Mississippi Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2010
NCT01103180
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

University of Southern Mississippi

Active Ingredients

Drugs in Phase 2 Trials (1)

escitalopram (lexapro) (1 trial)

Drugs in Other Trials (1)

ketone monoester (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Borderline Personality Disorder (Phase 2)

Disease (Phase 2)

Personality Disorders (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2